Cargando…
PD-L1 expression in malignant salivary gland tumors
BACKGROUND: Programmed death-1 ligand-1 (PD-L1) an important cancer biomarker that can suppress the immune system and its high expression is often reported to be related with increased tumor aggressiveness in some cancers. Here, we examined and evaluated PD-L1 expression in patients with malignant s...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801834/ https://www.ncbi.nlm.nih.gov/pubmed/29409471 http://dx.doi.org/10.1186/s12885-018-4069-3 |
_version_ | 1783298418437783552 |
---|---|
author | Harada, Koji Ferdous, Tarannum Ueyama, Yoshiya |
author_facet | Harada, Koji Ferdous, Tarannum Ueyama, Yoshiya |
author_sort | Harada, Koji |
collection | PubMed |
description | BACKGROUND: Programmed death-1 ligand-1 (PD-L1) an important cancer biomarker that can suppress the immune system and its high expression is often reported to be related with increased tumor aggressiveness in some cancers. Here, we examined and evaluated PD-L1 expression in patients with malignant salivary gland tumor. Moreover, the relationship between PD-L1 immunolocalization and clinical pathological features, as well as the prognosis of malignant salivary gland tumors was investigated. METHODS: We examined PD-L1expression in 47 patients with malignant salivary gland tumor by immunohistochemical staining. PD-L1 positivity was defined as ≥5% in tumor cell membrane and evaluated according to three categories (0% = 0, < 5% = 1, ≥5% = 2) in tumor-infiltrating mononuclear cells (TIMCs). Fisher’s exact test was used to compare between PD-L1 expression and clinico-pathological features, and Kaplan–Meier method was used to estimate the distribution of OS by PD-L1 positivity. RESULTS: PD-L1 expression was detected in 51.1% of malignant salivary gland tumor tissues. No association was observed between PD-L1 immunolocalization in tumor and patient gender, or age. However, PD-L1 immunodetection of tumor cell membranes was significantly associated to stage, recurrence or metastasis after surgery, and patient outcome. On the other hand, PD-L1 immunodetection of tumor-infiltrating mononuclear cells (TIMCs) was significantly associated to recurrence or metastasis after surgery, and patient outcome. PD-L1 positivity in both tumor cell membrane and TIMCs was associated with shorter overall survival (OS) (p = 0.002 and p = 0.016, respectively). CONCLUSION: These findings suggested that patients with PD-L1 positive tumors or TIMCs appear to have poor clinical outcomes in malignant salivary gland tumors. |
format | Online Article Text |
id | pubmed-5801834 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-58018342018-02-14 PD-L1 expression in malignant salivary gland tumors Harada, Koji Ferdous, Tarannum Ueyama, Yoshiya BMC Cancer Research Article BACKGROUND: Programmed death-1 ligand-1 (PD-L1) an important cancer biomarker that can suppress the immune system and its high expression is often reported to be related with increased tumor aggressiveness in some cancers. Here, we examined and evaluated PD-L1 expression in patients with malignant salivary gland tumor. Moreover, the relationship between PD-L1 immunolocalization and clinical pathological features, as well as the prognosis of malignant salivary gland tumors was investigated. METHODS: We examined PD-L1expression in 47 patients with malignant salivary gland tumor by immunohistochemical staining. PD-L1 positivity was defined as ≥5% in tumor cell membrane and evaluated according to three categories (0% = 0, < 5% = 1, ≥5% = 2) in tumor-infiltrating mononuclear cells (TIMCs). Fisher’s exact test was used to compare between PD-L1 expression and clinico-pathological features, and Kaplan–Meier method was used to estimate the distribution of OS by PD-L1 positivity. RESULTS: PD-L1 expression was detected in 51.1% of malignant salivary gland tumor tissues. No association was observed between PD-L1 immunolocalization in tumor and patient gender, or age. However, PD-L1 immunodetection of tumor cell membranes was significantly associated to stage, recurrence or metastasis after surgery, and patient outcome. On the other hand, PD-L1 immunodetection of tumor-infiltrating mononuclear cells (TIMCs) was significantly associated to recurrence or metastasis after surgery, and patient outcome. PD-L1 positivity in both tumor cell membrane and TIMCs was associated with shorter overall survival (OS) (p = 0.002 and p = 0.016, respectively). CONCLUSION: These findings suggested that patients with PD-L1 positive tumors or TIMCs appear to have poor clinical outcomes in malignant salivary gland tumors. BioMed Central 2018-02-06 /pmc/articles/PMC5801834/ /pubmed/29409471 http://dx.doi.org/10.1186/s12885-018-4069-3 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Harada, Koji Ferdous, Tarannum Ueyama, Yoshiya PD-L1 expression in malignant salivary gland tumors |
title | PD-L1 expression in malignant salivary gland tumors |
title_full | PD-L1 expression in malignant salivary gland tumors |
title_fullStr | PD-L1 expression in malignant salivary gland tumors |
title_full_unstemmed | PD-L1 expression in malignant salivary gland tumors |
title_short | PD-L1 expression in malignant salivary gland tumors |
title_sort | pd-l1 expression in malignant salivary gland tumors |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801834/ https://www.ncbi.nlm.nih.gov/pubmed/29409471 http://dx.doi.org/10.1186/s12885-018-4069-3 |
work_keys_str_mv | AT haradakoji pdl1expressioninmalignantsalivaryglandtumors AT ferdoustarannum pdl1expressioninmalignantsalivaryglandtumors AT ueyamayoshiya pdl1expressioninmalignantsalivaryglandtumors |